Ascilion AB, the leader in dermal interstitial fluid sampling, announced an investment by Lotus One Investment Pte. Ltd. in the company.
Ascilion AB, the leader in dermal interstitial fluid sampling for molecular biomarker research, diagnostics and wearables announced an investment of SEK 21 million by Lotus One Investment Pte. Ltd. (“Lotus”) in the company.
The investment by Lotus in Ascilion was through the combination of a SEK 21 million directed share issue and an additional purchase of existing shares. The investment positions Lotus as a key shareholder and grants them representation on the Ascilion’s board of directors, with Asmita Dwivedi recently appointed as a board member.
Read More on Fintech : Reinventing Identity Security in the Age of AI
Nirmal Singh, Executive Chairman of Lotus, commented: “Lotus is committed to supporting innovations that promote the democratization of healthcare services, and we believe that Ascilion, through their unique technology, can enable new health monitoring capabilities as well as improve the accessibility and equity of diagnostics and monitoring services.”
Simon Grant, CEO of Ascilion, commented: “We are very pleased to welcome Lotus as a major shareholder. We share a common vision that Ascilion’s technology will be central to the development of many point-of-care and wearable diagnostic devices in the future. We look forward to our journey together.”
Catch more Fintech Insights : The Future of Banking Starts with Customers
[To share your insights with us, please write to psen@itechseries.com ]
